All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Search results for “”
Show results per page.
Showing 276–300 of 1300 results.
8.4.3 Antifolates
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-3-antifolates 8.4.4 Antimetabolites
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-4-antimetabolites 8.4.5 Cytotoxic antibiotics
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-5-cytotoxic-antibiotics 8.4.6 Drugs for cytotoxic-induced side effects
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-6-cytotoxic-side-effects 8.4.7 Nucleoside analogues
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-7-nucleoside-analogues 8.4.8 Platinum compounds
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-8-platinum-compounds 8.4.9 Podophyllotoxins
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-9-podophyllotoxins 8.4.10 Taxanes
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-10-taxanes 8.4.11 Topoisomerase I inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-11-topoisomerase-i-inhibitors 8.4.12 Vinca alkaloids
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-12-vinca-alkaloids 8.4.13 Other cytotoxic antineoplastics
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-13-other-cytotoxic-antineoplastics 8.5.1 Epidermal growth factor receptor (EGFR) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-1-epidermal-growth-factor-receptor-egfr-inhibitors 8.5.2 Human epidermal growth factor receptor (HER2) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-2-human-epidermal-growth-factor-receptor-her2-inhibitors 8.5.3 Histone deacetylase (HDAC) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-3-histone-deacetylase-hdac-inhibitors 8.5.4 Immunomodulatory agents (IMiDs)
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-4-immunomodulatory-agents-imids 8.5.5 Mammalian target of rapamycin (mTOR) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-5-mammalian-target-of-rapamycin-mtor-inhibitors 8.5.6 Mitogen-activated protein kinase (MAPK) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-6-mitogen-activated-protein-kinase-mapk-inhibitors 8.5.7 Mitotic inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-7-mitotic-inhibitors 8.5.8 Monoclonal antibodies
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-8-monoclonal-antibodies 8.5.9 Multikinase inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-9-multikinase-inhibitors 8.5.10 Proteasome inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-10-proteasome-inhibitors 8.5.11 Retinoids
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-11-retinoids 8.5.12 Tyrosine kinase inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-12-tyrosine-kinase-inhibitors 8.5.13 VEGF / VEGFR inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-13-vegf-vegfr-inhibitors 8.6.1 Cyclin-dependent kinase (CDK) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-6-miscellaneous-antineoplastics/8-6-1-cyclin-dependent-kinase-cdk-inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-3-antifolates 8.4.4 Antimetabolites
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-4-antimetabolites 8.4.5 Cytotoxic antibiotics
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-5-cytotoxic-antibiotics 8.4.6 Drugs for cytotoxic-induced side effects
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-6-cytotoxic-side-effects 8.4.7 Nucleoside analogues
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-7-nucleoside-analogues 8.4.8 Platinum compounds
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-8-platinum-compounds 8.4.9 Podophyllotoxins
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-9-podophyllotoxins 8.4.10 Taxanes
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-10-taxanes 8.4.11 Topoisomerase I inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-11-topoisomerase-i-inhibitors 8.4.12 Vinca alkaloids
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-12-vinca-alkaloids 8.4.13 Other cytotoxic antineoplastics
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-4-cytotoxic-antineoplastics/8-4-13-other-cytotoxic-antineoplastics 8.5.1 Epidermal growth factor receptor (EGFR) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-1-epidermal-growth-factor-receptor-egfr-inhibitors 8.5.2 Human epidermal growth factor receptor (HER2) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-2-human-epidermal-growth-factor-receptor-her2-inhibitors 8.5.3 Histone deacetylase (HDAC) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-3-histone-deacetylase-hdac-inhibitors 8.5.4 Immunomodulatory agents (IMiDs)
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-4-immunomodulatory-agents-imids 8.5.5 Mammalian target of rapamycin (mTOR) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-5-mammalian-target-of-rapamycin-mtor-inhibitors 8.5.6 Mitogen-activated protein kinase (MAPK) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-6-mitogen-activated-protein-kinase-mapk-inhibitors 8.5.7 Mitotic inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-7-mitotic-inhibitors 8.5.8 Monoclonal antibodies
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-8-monoclonal-antibodies 8.5.9 Multikinase inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-9-multikinase-inhibitors 8.5.10 Proteasome inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-10-proteasome-inhibitors 8.5.11 Retinoids
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-11-retinoids 8.5.12 Tyrosine kinase inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-12-tyrosine-kinase-inhibitors 8.5.13 VEGF / VEGFR inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-5-targeted-antineoplastics/8-5-13-vegf-vegfr-inhibitors 8.6.1 Cyclin-dependent kinase (CDK) inhibitors
https://northeast.devonformularyguidance.nhs.uk/formulary/chapters/8-immunomodulatory-treatments-and-malignant-disease/8-6-miscellaneous-antineoplastics/8-6-1-cyclin-dependent-kinase-cdk-inhibitors
